



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: May 13, 2011

To: Primary Clinical Research Associates

From: Sara Braun
Protocol Development Coordinator

Re: N078D, Phase I/II Trial of Rituximab, Cladribine, and Temsirolimus (RCT)
Therapy in Newly Diagnosed Mantle Cell Lymphoma (MCL)

Attached is this new form for the protocol. Edits are as follows:

CRF Title	Brief Description of Edit
Quantitative Flow Cytometry Form (Baseline)	<ul style="list-style-type: none">• New form

If you have any questions, please feel free to contact me.

Enclosure